Cancer Prevention Pharmaceuticals
Cancer Prevention Pharmaceuticals is a Tucson company built around eflornithine, the polyamine-blocking drug, which it tested with sulindac in phase 3 to prevent polyps in familial adenomatous polyposis.
Overview
Cancer Prevention Pharmaceuticals, founded in 2008 in Tucson, Arizona, develops eflornithine (DFMO), an ornithine decarboxylase inhibitor, for cancer prevention. Its phase 3 trials combined eflornithine with sulindac in familial adenomatous polyposis and in patients with a history of colorectal adenomas, registered on ClinicalTrials.gov under the company as lead sponsor; the combination did not reach approval, though eflornithine itself was later approved by another company for neuroblastoma maintenance.
Similar pages
not linked directly; found by shared links- CompanyAeterna Zentaris
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyNorgine
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyZeria Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.